Clinical Trial Update: Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety and immunogenicity of the tuberculosis vaccine M72/AS01E in people with well-controlled HIV, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• M72/AS01E (M72/AS01E)

Snippet

Sponsor: Gates Medical Research Institute | Conditions: Human Immunodeficiency Virus | Phase 2 | Status: COMPLETED | Results posted: 2025-07-17